Clinical Trials in France / NCT06535243
Recruiting
Not applicable
Evaluation of the Efficacy of "Lifespan Integration" (LI) Therapy in Patients With Complex Post-Traumatic Stress Disorder
NCT06535243 · tracked via the Priya Life Science France tracker
Condition(s) studied
Post-Traumatic Stress Disorder ComplexPsychiatric DisorderAbuse NeglectAbuse PhysicalAbuse, SexualAbuse DomesticAbuse Verbal
Investigational drug(s) / intervention(s)
Lifespan Integration Therapy (LI)
Lifespan Integration Therapy (LI): same as above
Study summary
The study aims to evaluate the efficacy of a relatively new type of psychotherapy called Lifespan Integration (LI) in patients suffering of complex PTSD
Eligibility
Inclusion Criteria:
* patients diagnosed with complex PTSD
* French speaking
* first time following an LI type of therapy
* psychotropic treatment is allowed
Exclusion Criteria:
* no other parallel psychotherapy is accepted (if the patient underwent recently any other type of psychotherapy, a "wash out " period of minimum 4 weeks is required )
* no active manic episode at the time of inclusion
* no active psychotic episode at the time of inclusion
* no chronic psychotic disorder diagnosis
* no autistic spectrum disorder diagnosis ,
* no intellectual deficit
Primary outcome measure(s)
- change of the scores of International Trauma Questionnaire — maximum one year
International Trauma Questionnaire measures subscores of simple and complex PTSD, the score is calculated using an algorithm, a minimum score of 8 for the PTSD simple part and of 8 for PTSD complex part is needed in order to diagnose a complex PTSD; the maximum score for simple PTSD is 16, same for complex PTSD.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU St Anne | Paris | Île-de-France Region | Recruiting |
More Centre Hospitalier St Anne trials in France
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06535243 on ClinicalTrials.gov ↗ ← All trials in France